Clinical Trials Logo

Postoperative Blood Loss clinical trials

View clinical trials related to Postoperative Blood Loss.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05889494 Recruiting - Clinical trials for Postoperative Hemorrhage

Autologous Whole Blood Management for Transfusion Reduction in Adult Cardiac Surgery Patients

Start date: June 5, 2024
Phase: N/A
Study type: Interventional

The goal of this pilot trial is to test a protocol for a planned Canada-wide clinical trial looking at whether or not the use of a patients own blood works as good as the current standard of care using donated blood products to reduce blood loss in adult patients having heart surgery. The main questions this study aims to answer are: - Is the protocol practical, effective, and efficient. - Does the use of a patients own blood lower the following: bleeding, the amount donated blood products given, and complications. Participants will be separated into two groups by a process that is like flipping a coin. One group will donate blood to themselves in the operating room and get their own blood back after surgery. The other group will be given blood products donated by other humans to treat the bleeding after heart surgery. Researchers will compare both groups to see if patients that get their own blood have fewer donated blood products given at time of heart surgery and have less complications after surgery.

NCT ID: NCT05774717 Recruiting - Surgery Clinical Trials

Tranexamic Acid in Rhinoplasty: Perioperative Bleeding, Edema and Ecchymosis

Start date: April 1, 2023
Phase: Phase 1
Study type: Interventional

This study will be a prospective randomized study to evaluate the effect of tranexamic acid (TXA) use on intraoperative and postoperative outcomes among patients undergoing rhinoplasty by two Facial Plastic surgeons at Vanderbilt. Outcomes will include intra- and post-operative bleeding and postoperative bruising and swelling.

NCT ID: NCT05047133 Recruiting - Clinical trials for Postoperative Blood Loss

Effect of Early Administration of TXA in Adult Hip Fractures

Start date: September 1, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

This is a prospective clinical study designed to assess blood loss in intracapsular and extracapsular hip fractures undergoing operative fixation at a Level II trauma center. It is well established in the orthopedic literature that tranexamic acid (TXA) decreases blood loss and need for postoperative blood transfusion in hip fracture patients as well as total joint arthroplasty patients. A typical dosing pattern, and the dosing pattern employed at our institution, is 1 gram IV infused prior to incision followed by 1 gram IV infused at the time of wound closure.